Brokerages Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) PT at $8.50

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has received a consensus rating of “Buy” from the ten research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $8.50.

A number of research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a report on Tuesday, February 3rd. Wall Street Zen cut Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Finally, Piper Sandler raised their target price on shares of Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday, November 7th.

Institutional Investors Weigh In On Aquestive Therapeutics

Several institutional investors have recently added to or reduced their stakes in AQST. Vanguard Group Inc. increased its holdings in Aquestive Therapeutics by 30.8% during the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after purchasing an additional 1,333,627 shares in the last quarter. State Street Corp boosted its position in shares of Aquestive Therapeutics by 53.7% during the fourth quarter. State Street Corp now owns 2,462,778 shares of the company’s stock worth $15,910,000 after buying an additional 860,562 shares during the period. Geode Capital Management LLC grew its holdings in shares of Aquestive Therapeutics by 13.4% during the fourth quarter. Geode Capital Management LLC now owns 2,368,092 shares of the company’s stock worth $15,301,000 after buying an additional 280,144 shares in the last quarter. Federated Hermes Inc. raised its position in Aquestive Therapeutics by 159.4% in the 4th quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock valued at $13,132,000 after buying an additional 1,249,044 shares during the last quarter. Finally, Pale Fire Capital SE raised its position in Aquestive Therapeutics by 25.5% in the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock valued at $5,549,000 after buying an additional 340,767 shares during the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Stock Up 1.2%

Shares of AQST stock opened at $4.14 on Thursday. Aquestive Therapeutics has a 12-month low of $2.12 and a 12-month high of $7.55. The firm has a fifty day moving average of $4.46 and a 200-day moving average of $5.19. The firm has a market capitalization of $505.08 million, a price-to-earnings ratio of -5.83 and a beta of 1.65.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.